Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02393417
Other study ID # CFW-2D
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2015
Est. completion date March 2018

Study information

Verified date May 2019
Source Nielsen BioSciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the exception of unblinded dedicated staff to handle study medication), phase 2a study with 3 dose cohorts, randomized (concealed) to CANDIN or placebo (3:1). Main study will be up to 20 weeks (10 doses administered every other week) or until a subject has complete resolution of all injectable common warts. Subjects who cannot tolerate dosing every 2 weeks due to a local tolerance issue may be injected at 3-week intervals for up to 10 doses, increasing the length of the study to 29 weeks. Subjects will be followed for 4 months after final injection(s) for evidence of new or reoccurring warts and for safety evaluation.


Recruitment information / eligibility

Status Completed
Enrollment 243
Est. completion date March 2018
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Men or women between the ages of 18 and 65 years inclusively at time of consent

2. Subjects presenting with 3 to 20 injectable common warts (verruca vulgaris) for at least 12 weeks at the time of the Baseline Visit

3. Subject's common warts for injection must measure between 3 and 20 mm at Baseline Visit and be located on hands, feet (excluding soles), limbs, and/or trunk. Flat, plantar, facial, periungual, genital warts or warts in region of pre-existing inflammatory condition are excluded from injection

4. Subjects enrolled into Cohort 3 must have common warts for injection in at least 2 different anatomical regions defined as: left arm, right arm, left hand, right hand, left leg, right leg, left foot (excluding sole), right foot (excluding sole) and torso

5. Subject, male or female is willing to use effective contraceptive method for at least 30 days before the Baseline Visit and at least 30 days after the last study drug administration unless not of childbearing potential as defined as post-menopausal for at least 2 years (females) or surgically sterile (tubal ligation, oophorectomy, or hysterectomy for females, and vasectomy for males). The only contraceptive use exceptions would be individuals in exclusive same sex partnerships and individuals who agree to remain non-sexually active for the duration of the study. Acceptable contraceptive methods for subjects include:

- Barrier methods, such as condom, sponge or diaphragm, combined with spermicide in foam, gel or cream;

- Hormonal contraception (oral, intramuscular, implant or transdermal which includes Depo-Provera, Evra and Nuvaring);

- Intrauterine device (IUD)

6. Mentally and legally capable of giving informed consent prior to any study related procedures

Exclusion Criteria:

1. Presence of systemic or localized diseases, conditions, or medications that could interfere with assessment of safety and efficacy or that compromise immune function including psoriasis

2. Subject has been diagnosed with diabetes mellitus

3. Subject has a history of keloid formation

4. Injectable common wart(s) located in areas with existing dermatologic conditions (such as psoriasis) or with an underlying inflammatory conditions (such as arthritic joints), or tattoos or implants/piercing/hardware or marking that may conceal responses or reactions are excluded from injection

5. Existing/planned pregnancy, childbirth in the past six months prior to the Baseline Visit, or breast feeding, or plan on donating eggs or sperm during the study and in the month following the last injection

6. Treatment of warts with liquid nitrogen, carbon dioxide, electrodessication, laser, surgery, simple occlusion (e.g. duct tape) salicylic or related acids, OTC treatments, cantharidin, or other treatments within 4 weeks of the Baseline Visit

7. Treatment with immunotherapy (DPCP, DNCB or other), imiquimod, 5-fluorouracil, bleomycin, podophyllin or any other wart immunotherapy or treatment designed to stimulate immune response (except for treatments already listed in exclusion criterion 6) within 12 weeks of the Baseline Visit

8. Recalcitrant warts defined as those not successfully treated by 5 or more treatments (excluding OTC treatments)

9. Abnormal (low < 5 mm or high >25 mm) baseline result to the Delayed Type Hypersensitivity (DTH) test

10. Subject has a condition or treatment resulting in being immunocompromised

11. Systemic treatment (such as oral or injected) with cimetidine, zinc supplements at a dose higher than 20 mg of elemental zinc daily or an immunosuppressive drug (such as: azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, systemic steroids, etc.) within 12 weeks of the Baseline Visit

12. Subject has used any investigational agent within 30 days prior to the Baseline Visit or within 5 half-lives of that investigational agent prior to the Baseline Visit (whichever is longer)

13. Previous treatment of warts with any type of intralesional injection with candida extract (including CANDIN)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CANDIN
Candida albicans Skin Test Antigen for Cellular Hypersensitivity
Other:
Placebo
0.9% Sodium Chloride Injection USP (non-preserved)

Locations

Country Name City State
United States Austin Institute for Clinical Research Inc. Austin Texas
United States DermResearch Inc. Austin Texas
United States California Dermatology and Clinical Research Institute Encinitas California
United States Hamzavi Dermatology Clinical Trials Fort Gratiot Michigan
United States Johnson Dermatology Fort Smith Arkansas
United States Minnesota Clinical Study Center Fridley Minnesota
United States Dermatology Consulting Services High Point North Carolina
United States The Education and Research Foundation, Inc. Lynchburg Virginia
United States Metro Boston Clinical Partners, LLC Needham Massachusetts
United States Silverberg MD Inc. Newport Beach California
United States Oregon Medical Research Center Portland Oregon
United States Northwest Arkansas Clinical Trials Center PLLC Rogers Arkansas
United States Dermatology Research Center, Inc. Salt Lake City Utah
United States Texas Dermatology and Laser Specialists San Antonio Texas
United States BayState Clinical Trials Watertown Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Nielsen BioSciences, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O'Bryan K, Myers J, Nakagawa M. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010 Dec;146(12):1431-3. doi: 10.1001/archdermatol.2010.350. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Association Between the Age of the Largest Primary Injected Wart and Complete Resolution of the Largest Primary Injected Wart Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart 45 weeks
Other Association Between the Age of the Primary Injected Wart and the Recurrence of Any Resolved Wart at Any Visit. 45 weeks
Other Summary of Complete Resolution of the Largest Primary Wart and Type of Treatment History Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart 45 weeks
Other The Effect of the Treatment History on the Number of Recurrences of Resolved Primary Warts 45 weeks
Primary Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart 45 weeks
Secondary Number of Subjects With a Complete Resolution of All Common Warts at Any Treatment or Follow-up Visit Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart 45 weeks
Secondary Number of Subjects With Complete Resolution of Primary Injected Wart(s) at the 4 Month Follow-up Visit Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart 4 month follow up visit at 45 weeks
Secondary Number of Injection Visits Needed to Obtain Complete Resolution of the Primary Injected Wart(s) Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart 45 weeks
Secondary Number of Injection Visits for >50% Reduction in Area of the Primary Injected Wart(s) 45 weeks
Secondary Number of Injection Visits to >50% Reduction in the Total Area of All Measured Warts 45 weeks
Secondary Number of Subjects With Scarring at the Site of Resolved Primary and Non-primary Injected Wart(s) Scarring at any visit, many reports were transient being noted at only one or two visits and noted as resolving during the course of the study 45 weeks
Secondary Number of Subjects With Hypopigmentation at the Site of Resolved Primary and Non-primary Injected Wart(s) 45 weeks
Secondary Number of Subjects With Injection Site Reactions With Frequency Greater Than 5% 45 weeks
See also
  Status Clinical Trial Phase
Completed NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts Phase 2
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Withdrawn NCT00546611 - The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s) Phase 1
Completed NCT00117871 - Study With a Topical Gel to Treat Common Warts in Adults Phase 2
Completed NCT04278573 - Intralesional Vitamin D Injection for Treatment of Common Warts Phase 2
Completed NCT02231879 - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Phase 2/Phase 3
Completed NCT06309420 - Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts N/A
Not yet recruiting NCT05616078 - Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts N/A
Not yet recruiting NCT05617950 - Salicylic Acid Versus Cryotherapy for the Treatment of HPV1-induced Plantar Warts N/A
Recruiting NCT01712295 - 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Phase 4
Active, not recruiting NCT00254280 - Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial N/A
Completed NCT04781244 - Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment N/A
Completed NCT01101750 - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase 4
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Recruiting NCT05625633 - Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts Phase 2/Phase 3
Completed NCT01808443 - Efficacy of Laser Versus Cryotherapy in the Treatment of Warts N/A
Completed NCT00116662 - An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2
Completed NCT00116675 - Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2
Completed NCT00114920 - Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults Phase 2